Business Wire - August 23, 2004
Millennium Biotechnologies, Inc. a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. is pleased to announce yet another major study validating the crucial benefits of SOD/Gliadin (DefenZyme(TM)) in reducing oxidative stress in humans.
Millennium owns the exclusive North American rights in the medical market to the body's primary antioxidant defense enzyme, SOD/Gliadin (Defenzyme(TM)), which is an orally effective form of Superoxide dismutase, a key ingredient in the Company's flagship products Resurgex(R), Resurgex Plus(TM) and Defenzyme(TM). These products are proprietary nutritional formulas designed as adjuncts to conventional medical care.
The double blind randomized study, titled "Influence of An Orally Effective SOD On Hyperbaric Oxygen Related Cell Damage" was performed at the University Hospital in Ulm, Germany, and investigated the use of SOD/Gliadin in protecting humans against oxidative stress.
"With statistical significance, SOD/Gliadin was shown to protect the part of the cell that produces energy (mitochondria) from the genetic damage that occurs in the presence of oxidative stress. In addition to protecting mitochondrial DNA, the effectiveness of SOD/Gliadin was also supported by the significantly reduced levels of isoprostanes in the blood, a recognized measure of cellular oxidative damage," states Carl Germano, RD, CNS, CDN, vice president, Research & Product Development, Millennium Biotechnologies.
"Protecting the energy producing part of the cell from oxidative stress is a critical component in addressing the nutritional needs of immuno-compromised individuals, such as those dealing with Cancer and HIV/Aids, which cannot be met with traditional nutritional formulas currently on the market.
"Existing formulas are typically loaded with sugar (corn syrup) and fat (corn oil), which can have an adverse effect on these patients, who typically suffer from glucose dysregulation (pre diabetes) and lipid abnormalities. This study, along with others that show how SOD/Gliadin can lower lactic acid, also demonstrates the importance of using SOD/Gliadin in sports applications as the energy producing part the cells are sensitive to the excess free radicals that are produced after strenuous exercise," states Germano.
The announcement is yet another important milestone in establishing the efficacy and clinical significance of SOD/Gliadin. As such, it has been accepted for publication in the peer-reviewed journal Free Radical Research. While this is among the first significant human study primed for publication, many other animal and human studies support the use of SOD/Gliadin in nutritional applications for immune and antioxidant support and sports nutrition.
Complete study results are available upon request.
About Millennium Biotechnologies
Millennium Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies, Group Inc. is a pioneer in the research and development and marketing of medical nutritional supplements. Millennium owns the exclusive rights to RESURGEX(R) and RESURGEX Plus(TM), multiple action nutritional formulas containing the critically important, orally effective form of (SOD)/Gliadin (Defenzyme(TM))) and several other essential nutritional components. Millennium products are designed to assist in increasing energy, maintaining lean muscle, reducing oxidative stress and supporting immune function in patients with HIV/AIDS, Hepatitis C, cancer or other immuno-compromised conditions as an adjunct to their medical care. Additional information about Millennium Biotechnologies, Inc., is available at www.milbiotech.com.
This news release contains forward-looking statements that are based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions on the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.
CONTACT: KCSA
Anne Donohoe or Katie Bestenlehner
212-896-1261 or 212-896-1269
adonohoe@kcsa.com or kbest@kcsa.com
SOURCE: Millennium Biotechnologies, Inc.
040823
BW040814
Copyright © 2004 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .